Learn more about whether Halozyme Therapeutics, Inc. or Zymeworks Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.
The subcutaneous formulation of the bispecific antibody reduces treatment time to 1 minute vs 2-4 hours with IV infusion.
Three years after its initial FDA approval, Roche has made up for an early disadvantage with its blood cancer drug Lunsumio ...
The FDA has granted approval to a subcutaneous formulation of mosunetuzumab (Lunsumio VELO; Genentech/Roche) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma ...
The U.S. Food and Drug Administration has approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the first and ...
The US FDA has approved mosunetuzumab-axgb (Lunsumio VELO) as a subcutaneous (SC) formulation for the treatment of adult ...
Clinical Trials Arena on MSN
Soligenix reports Phase IIa SGX945 trial data for Behçet’s disease
Soligenix has reported positive data from its Phase IIa trial of SGX945 (dusquetide) for the treatment of Behçet's disease. The proof-of-concept study examined SGX945 for treating oral ulcers in the ...
The FDA has granted accelerated approval to subcutaneous treatment with mosunetuzumab (Lunsumio VELO™), a CD20xCD3 bispecific antibody, for adult patients with relapsed or refractory follicular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback